The Food and Drug Administration (FDA) has granted approval to AQVESME (mitapivat), marking a historic milestone in the thalassemia treatment. As the first oral therapy indicated for adults with both non-transfusion-dependent (NTD) and transfusion-dependent (TD) alpha- or beta-thalassemia, this approval represents a transformative advancement for patients who have historically lacked effective therapeutic options.

The approval, granted on December 23, 2025, is anchored in robust clinical evidence from two pivotal Phase 3 trials—ENERGIZE and ENERGIZE-T—which demonstrated that mitapivat delivers statistically significant and clinically meaningful improvements in hemoglobin levels, patient-reported fatigue, and transfusion burden compared to placebo.

Know more on how Thalassemia treatment landscape is evolving @ https://www.delveinsight.com/report-store/thalassemia-market

AQVESME Clinical Efficacy: Translating Data into Patient Outcomes

The ENERGIZE-T trial, which enrolled patients with transfusion-dependent thalassemia, revealed compelling efficacy outcomes. Approximately 30.4% of patients receiving mitapivat achieved the primary endpoint of transfusion reduction response, defined as a ≥50% reduction in transfused red blood cell units with a reduction of ≥2 units of transfused RBCs in any consecutive 12-week period through week 48 compared with baseline. This was significantly superior to the placebo arm, where only 12.6% of patients achieved this response. Moreover, 9.9% of mitapivat-treated patients achieved complete transfusion independence, compared with 1.1% in the placebo group.

“This is a pivotal moment for the thalassemia community, introducing an innovative oral treatment that modifies disease and addresses the critical needs of those affected by this severe rare blood condition,” stated Brian Goff, Chief Executive Officer of Agios. “With this approval, AQVESME stands as the only medication indicated for treating anemia in non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia.”

Ralph Colasanti, President of the Cooley’s Anemia Foundation, underscored the significance of this development: “This year commemorates a century since thalassemia was first documented in medical texts, and the achievements we’ve made as a community are remarkable. Breakthroughs like AQVESME facilitate this progress, providing hope to patients by addressing the intricate needs and challenges posed by this condition. This approval introduces a crucial treatment option for the thousands of adults living with thalassemia in the U.S., especially for those with non-transfusion-dependent forms who previously lacked approved treatments.”

Addressing a Significant Unmet Need in a Substantial Patient Population

Globally, thalassemia represents a substantial disease burden. In 2021, the worldwide number of thalassemia cases reached approximately 1.31 million, with an age-standardized prevalence rate of 18.28 per 100,000 persons. The global incidence of thalassemia involved approximately 119,679 cases annually, with an age-standardized incidence rate of 1.93 per 100,000 persons. East Asia exhibits the highest prevalence at 54.26 per 100,000 persons, followed by Southeast Asia at 43.38 per 100,000 persons.

Within the United States specifically, there are at least 1,200 people with transfusion-dependent thalassemia, while more than 1 million people globally have non-transfusion-dependent thalassemia. Notably, alpha-thalassemia has historically lacked any FDA-approved therapies, leaving patients dependent on supportive care measures such as blood transfusions and iron chelation therapy.

Prior to this approval, no oral disease-modifying therapies had been approved for beta-thalassemia. The introduction of AQVESME represents a paradigm shift from purely supportive care toward targeted molecular intervention, offering patients—particularly those with NTD forms who previously had no approved options—a disease-modifying oral alternative.

AQVESME Mechanism of Action and Pharmacological Innovation

AQVESME works by activating pyruvate kinase R (PKR), an enzyme that plays a critical role in red blood cell energy metabolism. By enhancing PKR activity, mitapivat increases ATP production in red blood cells while reducing 2,3-diphosphoglycerate (2,3-DPG) levels. This biochemical optimization improves oxygen binding to hemoglobin and extends red blood cell survival, thereby alleviating anemia and reducing transfusion dependence in patients with thalassemia.

Risk Evaluation and Mitigation Strategy (REMS) Program Reflects Commitment to Patient Safety

While AQVESME’s efficacy profile is compelling, the FDA approval includes implementation of the AQVESME REMS program due to the risk of hepatocellular injury. During the clinical trials, five patients treated with mitapivat reported adverse reactions suggestive of hepatocellular injury within the first six months of treatment, with two cases requiring hospitalization. Across the trials involving 301 patients with thalassemia during the double-blind phase, hepatocellular injury occurred in 0.66% of AQVESME-treated patients.

To mitigate this risk, the REMS program mandates liver function testing (including ALT, AST, alkaline phosphatase, and total bilirubin with fractionation) at baseline, every four weeks for the first 24 weeks, and subsequently as clinically indicated. Prescribers must counsel patients about hepatocellular injury risk, and AQVESME is contraindicated in patients with cirrhosis. The most common adverse reactions reported in trials were headache and insomnia.

“The REMS program reflects our unwavering commitment to patient safety while ensuring that patients can access this transformative therapy,” emphasized the company in its regulatory communications.

Anticipated Market Entry and Commercial Launch Timeline

AQVESME is expected to become available in the United States in late January 2026, following the full implementation of the REMS program. In the U.S. healthcare system, mitapivat will be marketed under the AQVESME brand for thalassemia indications, while continuing to be sold as PYRUKYND® for pyruvate kinase (PK) deficiency—a separate indication for which the drug received FDA approval in 2022. Internationally, mitapivat will retain the PYRUKYND brand name for both PK deficiency and thalassemia indications in approved regions.

Regulatory Expansion and Future Pipeline Developments

Beyond the U.S. approval, regulatory momentum is building globally. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recently issued a favorable opinion on Agios’ marketing authorization application to expand PYRUKYND’s label for thalassemia in Europe, with a final ruling from the European Commission anticipated in early 2026.

Furthermore, Agios is advancing mitapivat’s development in sickle cell disease. Topline results from the RISE UP Phase 3 trial of mitapivat in sickle cell disease were reported in November 2025. The company anticipates conducting a pre-supplemental New Drug Application (sNDA) meeting with the FDA in the first quarter of 2026, with a U.S. regulatory submission for sickle cell disease anticipated to follow.

Additionally, Agios is developing tebapivat, a more potent, once-daily oral PK activator, in Phase 2 trials for sickle cell disease. Enrollment was initiated in 2025, with topline results expected in the second half of 2026.

Thalassemia Competitive Landscape and Market Positioning

While AQVESME establishes itself as the only FDA-approved therapy specifically indicated for both NTD and TD thalassemia, the broader hemoglobinopathy market encompasses emerging competitors. According to market intelligence data, other players including Novo Nordisk (developing etavopivat, a pyruvate kinase R activator in Phase II/III for alpha-thalassemia) and Bristol-Myers Squibb (investigating REBLOZYL® and other TGF-beta superfamily protein inhibitors) are advancing late-stage candidates. Gene therapies such as CASGEVY® and ZYNTEGLO® represent alternative curative approaches, though their accessibility and applicability remain limited by factors including donor availability, cost, and logistical constraints.

Clinical Expert Perspective and Real-World Application

Dr. Maria Domenica Cappellini, Professor of Internal Medicine at the University of Milan, provided clinical context: “Mitapivat represents a good alternative option to luspatercept because patients respond differently to one drug over the other. So, mitapivat treatment can be an opportunity for those who are not responding to luspatercept.” This observation highlights the potential for mitapivat to address treatment heterogeneity and offer patients additional therapeutic flexibility within an expanding thalassemia treatment armamentarium.

Implications for Patient Care and Future Directions

The FDA approval of AQVESME marks a fundamental shift in thalassemia management. For transfusion-dependent patients, the demonstrated reduction in transfusion burden carries implications extending beyond anemia correction—including reduced iron overload, decreased risk of alloimmunization, and improvements in quality of life and functional capacity. For non-transfusion-dependent patients, who previously lacked any FDA-approved therapies and often endured symptom burden and disease progression, AQVESME offers a disease-modifying oral option with meaningful clinical benefit potential.

As Agios moves forward with its commercial execution and continued pipeline expansion, the thalassemia community—patients, caregivers, healthcare providers, and advocacy organizations—await the real-world translation of these clinical trial findings into sustained therapeutic impact.

About Thalassemia

Thalassemia is an inherited blood disorder characterized by reduced or absent production of alpha or beta-globin chains, resulting in ineffective erythropoiesis, chronic anemia, iron overload from transfusions or increased absorption, and complications including organ damage, blood clots, and cardiac disease. Patients with transfusion-dependent forms require regular blood transfusions and iron chelation therapy, while those with non-transfusion-dependent forms experience variable clinical presentations ranging from mild anemia to significant symptomatic burden.

About AQVESME (mitapivat)

AQVESME is an oral pyruvate kinase R (PKR) activator indicated for the treatment of anemia in adults with alpha- or beta-thalassemia. The drug’s approval is based on data from the global Phase 3 ENERGIZE and ENERGIZE-T trials, which enrolled a combined 452 patients reflective of the broader thalassemia population.

Indication: AQVESME is indicated for the treatment of anemia in adults with alpha- or beta-thalassemia.

Important Safety Information: AQVESME can cause hepatocellular injury. Liver function testing is required at baseline, every four weeks for 24 weeks, and subsequently as clinically indicated. AQVESME should be avoided in patients with cirrhosis. The drug is available only through the AQVESME REMS program. Most common adverse reactions include headache and insomnia.